With a robust background in technology and healthcare investments, the fund manager has successfully completed over 30 deals across North America and Europe. Emphasizing a data-driven approach, they have cultivated a diverse portfolio that includes several notable exits, particularly in the biotech sector. Their strategic focus on early to growth-stage companies allows for maximizing value creation while driving innovation. Leveraging deep industry insights, the manager employs a thematic investment style that identifies emerging trends and market opportunities.